CXCR4 Antibody (44708) [Unconjugated]

Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF‑1 alpha (Catalog # 350-NS) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human/Feline/Rhesus Macaque CXCL12/SDF‑1 alpha (1 ng/mL) is neutralized (green line) by increasing concentrations of Human CXCR4 Monoclonal Antibody (Catalog # MAB171). The ND50 is typically 0.2-1.2 µg/mL.

Anti-CXCR4 antibody reduces CXCR4 surface expression, and blocks migration toward CXCL12 and BMSCs.(A) Relative MFIR of CXCR4 surface staining after incubation of Raji transfectants with 100 µg/mL of anti-CXCR4 antibody for 30 minutes. (B) Flow cytometry histograms showing the reduction in CXCR4 expression after incubation with neutralizing anti-CXCR4 antibody. White histograms represent negative unstained controls. (C) CXCR4-blocked cells were stimulated with 100 ng/mL of CXCL12 for 5 minutes and activation of Akt and ERK1/2 proteins analyzed by western blotting. (D) CXCR4-blocked cells were subjected to migration assay for 4 hours at 37°C in 5% CO2 toward 100 ng/mL of CXCL12 (left panel) or the stromal MS-5 cell line (right panel). Cells in the lower chamber were counted by flow cytometry under a defined flow rate for 5 minutes. Number of migrated cells treated with isotypic control was considered 100%. Results are shown as the mean ± SEM of 4 independent experiments. (E) Cell viability was measured by Annexin V-PI staining in cells incubated with 100 µg/mL of anti-CXCR4 or isotypic control for 48 hours. Results are shown as the mean ± SEM of 4 independent experiments Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081221), licensed under a CC-BY license. Not internally tested by R&D Systems.

Anti-CXCR4 antibody reduces CXCR4 surface expression, and blocks migration toward CXCL12 and BMSCs.(A) Relative MFIR of CXCR4 surface staining after incubation of Raji transfectants with 100 µg/mL of anti-CXCR4 antibody for 30 minutes. (B) Flow cytometry histograms showing the reduction in CXCR4 expression after incubation with neutralizing anti-CXCR4 antibody. White histograms represent negative unstained controls. (C) CXCR4-blocked cells were stimulated with 100 ng/mL of CXCL12 for 5 minutes and activation of Akt and ERK1/2 proteins analyzed by western blotting. (D) CXCR4-blocked cells were subjected to migration assay for 4 hours at 37°C in 5% CO2 toward 100 ng/mL of CXCL12 (left panel) or the stromal MS-5 cell line (right panel). Cells in the lower chamber were counted by flow cytometry under a defined flow rate for 5 minutes. Number of migrated cells treated with isotypic control was considered 100%. Results are shown as the mean ± SEM of 4 independent experiments. (E) Cell viability was measured by Annexin V-PI staining in cells incubated with 100 µg/mL of anti-CXCR4 or isotypic control for 48 hours. Results are shown as the mean ± SEM of 4 independent experiments Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081221), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: B/N
• Clone: 44708
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

CXCR4 Antibody (44708) [Unconjugated] Summary

• Immunogen: 3T3 cells transfected with human CXCR4
• Specificity: Reacts specifically with human and non-human cells expressing human CXCR4 (fusin) as detected by flow cytometry. It will also react with cells expressing feline CXCR4 but not rat CXCR4. This antibody does not cross-react with other chemokine receptors.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: CXCR4
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.2-1.2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCR4 Antibody (44708) [Unconjugated]

• CD184
• chemokine (C-X-C motif) receptor 4
• chemokine (C-X-C motif), receptor 4 (fusin)
• C-X-C chemokine receptor type 4
• CXCR4
• CXC-R4
• CXCR-4
• D2S201E
• D2S201ESDF-1 receptor
• FB22
• Fusin
• HM89
• HM89NPYRL
• HSY3RR
• LAP3
• LAP-3
• LCR1
• LESTR
• LESTRCD184 antigen
• Leukocyte-derived seven transmembrane domain receptor
• leukocyte-derived seven-transmembrane-domain receptor
• lipopolysaccharide-associated protein 3
• neuropeptide Y receptor Y3
• NPY3R
• NPY3RWHIM
• NPYR
• NPYRL
• NPYY3R
• pCXCR4
• seven transmembrane helix receptor
• seven-transmembrane-segment receptor, spleen
• Stromal cell-derived factor 1 receptor
• WHIMS

Background

CXCR4, also known as CD184, is a G-protein-linked seven transmembrane spanning receptor that binds stromal cell-derived factor-1 (SDF-1). CXCR4 acts as a co-factor for T-cell tropic HIV-1 and -2 viral entry into cells. While primarily a membrane protein, CXCR4 undergoes trafficking and internalization in response to stimulation with phorbol esters and ligand (1). Cytoplasmic and nuclear localization of CXCR4 has been observed in colorectal and renal carcinomas (2,3) and it has been used as the basis of prognosis and metastatic state (3,4,5).

1. Orsini, M.J. et al. (1999) J. Biol. Chem. 274:31076.
2. Zagzag, D. et al. (2005) Cancer Res. 65:6178.
3. Speetjens, F.M. et al. (2009) Cancer Microenvironment 2:1.
4. Wang, L. et al. (2009) Oncology Reports 22:1333.
5. Amara, S. et al. (2015) Cancer Biomark. 15:869.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCR4 Antibody (MAB171)(23)

Publications using MAB171

• SF Mause, E Ritzel, A Deck, F Vogt, EA Liehn Engagement of the CXCL12-CXCR4 Axis in the Interaction of Endothelial Progenitor Cell and Smooth Muscle Cell to Promote Phenotype Control and Guard Vascular Homeostasis International Journal of Molecular Sciences, 2022-01-14;23(2):. 2022-01-14 [PMID: 35055054] (Neutralization, Human)
• M Armani-Tou, Z Zhou, R Gasser, I Staropoli, V Cantaloube, Y Benureau, J Garcia-Per, M Pérez-Olme, V Lorin, B Puissant-L, L Assoumou, C Delaugerre, JD Lelièvre, Y Lévy, H Mouquet, G Martin-Blo, J Alcami, F Arenzana-S, J Izopet, P Colin, B Lagane Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis PloS Pathogens, 2021-04-19;17(4):e1009526. 2021-04-19 [PMID: 33872329] (Binding Assay, Human)
• F Caccuri, A Bugatti, S Corbellini, S Roversi, A Zani, P Mazzuca, S Marsico, A Caruso, C Giagulli The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3) Int J Mol Sci, 2019-10-24;20(21):. 2019-10-24 [PMID: 31653015] (Neutralization, Human)
• F Lüke, R Blazquez, RF Yamaci, X Lu, B Pregler, S Hannus, K Menhart, D Hellwig, HJ Wester, S Kropf, D Heudobler, J Grosse, J Moosbauer, M Hutterer, P Hau, MJ Riemenschn, M Bayerlová, A Bleckmann, B Polzer, T Bei beta barth, CA Klein, T Pukrop Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment Oncotarget, 2018-04-10;9(27):18844-18857. 2018-04-10 [PMID: 29721166] (FCCS, Human)
• M Mushtaq, L Jensen, S Davidsson, OV Grygoruk, O Andrén, V Kashuba, E Kashuba The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells Sci Rep, 2018-02-02;8(1):2268. 2018-02-02 [PMID: 29396484] (IHC-P, Human)
• SM Schwarzenb, J Stenzel, T Otto, HV Helldorff, C Bergner, J Kurth, S Polei, T Lindner, R Rauer, A Hohn, OW Hakenberg, HJ Wester, B Vollmar, BJ Krause [68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression Oncotarget, 2017-09-16;8(56):95606-95619. 2017-09-16 [PMID: 29221153] (IHC-P, Xenograft)
• Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices Proc Natl Acad Sci USA, 2016-08-19;0(0):. 2016-08-19 [PMID: 27543332] (IHC-Fr, Human)
• Zhu D, Wang Z, Zhao JJ et al. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat. Med. 5/25/2015 [PMID: 26005854]
• DiCosmo-Ponticello C, Hoover D, Coffman F, Cohen S, Cohen M MIF inhibits monocytic movement through a non-canonical receptor and disruption of temporal Rho GTPase activities in U-937 cells. Cytokine, 2014-06-06;69(1):47-55. 2014-06-06 [PMID: 25022961] (Neutralization, Human)
• Calpe E, Purroy N, Carpio C, Abrisqueta P, Carabia J, Palacio C, Castellvi J, Crespo M, Bosch F ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation. PLoS ONE, 2013-12-03;8(12):e81221. 2013-12-03 [PMID: 24312539] (Neutralization, Human)
• Pei Lin Shi, Beth Binnington, Darinka Sakac, Yulia Katsman, Stephanie Ramkumar, Jean Gariepy et al. Verotoxin A Subunit Protects Lymphocytes and T Cell Lines against X4 HIV Infection in Vitro Toxins (Basel) 2012-12-14 [PMID: 23242319]
• Fangyuan Wei, Douglas C Moore, Lei Wei, Yanlin Li, Ge Zhang, Xiaochun Wei et al. Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway Arthritis Research & Therapy 2012-07-31 [PMID: 22849584]
• Li Guo, Zhu-Mei Cui, Jia Zhang, Yu Huang Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma Chinese Journal of Cancer 2011-05-05 [PMID: 21527066]
• Claudia Rubie, Vilma O Frick , Pirus Ghadjar, Mathias Wagner, Christoph Justinger, Sabrina K Faust et al. CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells Journal of Translational Medicine 2011-12-01 [PMID: 21349176]
• Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, Couraud P, Cazaubon S IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cells. J Neuroimmunol, 2010-04-18;223(1):131-4. 2010-04-18 [PMID: 20400187] (Neutralization, Human)
• Wei L, Kanbe K, Lee M, Wei X, Pei M, Sun X, Terek R, Chen Q Stimulation of chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation. Dev. Biol., 2010-03-04;341(1):236-45. 3/4/2010 [PMID: 20206617]
• David Simons, Gerrit Grieb, Mihail Hristov, Norbert Pallua, Christian Weber, Jürgen Bernhagen et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment Journal of Cellular and Molecular Medicine 2011-03-01 [PMID: 20178462]
• Ouwehand K, Santegoets SJ, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. Eur. J. Immunol., 2008-11-01;38(11):3050-9. 2008-11-01 [PMID: 18924211] (Neutralization, Human)
• Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res., 2007-05-01;67(9):4244-53. 2007-05-01 [PMID: 17483336] (ICC, IHC-P, Western Blot, Human)
• Singh S, Singh UP, Grizzle WE, Lillard JW CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab. Invest., 2004-12-01;84(12):1666-76. 2004-12-01 [PMID: 15467730] (Neutralization, Human)
• Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E, Peled A Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur. J. Immunol., 2004-04-01;34(4):1164-74. 2004-04-01 [PMID: 15048728] (IHC-P, Human)
• Hatse S, Princen K, Vermeire K, Gerlach LO, Rosenkilde MM, Schwartz TW, Bridger G, De Clercq E, Schols D Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett., 2003-07-10;546(2):300-6. 2003-07-10 [PMID: 12832058] (Flow Cytometry, Human)
• Nguyen DH, Taub D CXCR4 function requires membrane cholesterol: implications for HIV infection. J. Immunol., 2002-04-15;168(8):4121-6. 2002-04-15 [PMID: 11937572] (Flow Cytometry, Neutralization, Human)

FAQs for CXCR4 Antibody (MAB171). (Showing 1 - 1 of 1 FAQs).

1. Which is your best CXCR4 for immunohistochemistry in paraffin tissues? I would like to detect it in paraffin embedded tissues from human breast cancer samples.
   • CXCR4 antibody (NB100-74396) is our best selling product among all the CXCR4 antibodies and it has been validated for IHC-P in human cervical carcinoma tissue sections. NB100-74396 has been cited in at least 7 research publications. Additionally, here is a list of all of our CXCR4 antibodies that has been verified in IHC-P in human samples.

Bioinformatics

• Gene Symbol: CXCR4